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ACE2 regulates central actions  
of angiotensin II
Angiotensin-converting enzyme 2 (ACE2) is a carboxypepti-
dase mainly expressed in the heart and kidney. Recent studies 
have shown ACE2 mRNA and protein in the brain, including in 
regions involved in the central regulation of cardiovascular func-
tion. ACE2 converts angiotensin (Ang) II into the vasodilatory 
peptide Ang(1–7) and has a 400-fold greater aﬃnity for Ang II than 
for Ang I. Although central Ang(1–7) has been shown to enhance 
baroreceptor reﬂex sensitivity, the role of ACE2 in central cardio-
vascular regulation remains unclear. Feng et al. examined whether, 
by increasing Ang(1–7) in the nervous system, ACE2 modulates the 
central actions of Ang II in cardiovascular function. They devel-
oped an adenovirus coding for human ACE2 cDNA upstream of 
an enhanced green ﬂuorescent protein (eGFP) reporter gene (Ad-
hACE2-eGFP). In vitro characterization showed that neuronal cells 
infected with Ad-hACE2-eGFP exhibited dose-dependent ACE2 
expression and activity in the mouse subfornical organ (Figure). 
Importantly, 7 days after virus infection, the pressor response to 
intracerebroventricular Ang II was signiﬁcantly reduced in Ad-
hACE2-eGFP-treated mice compared with controls. Further, sub-
fornical organ-targeted ACE2 overexpression dramatically reduced 
the Ang II-mediated drinking response. It is extremely interesting 
that ACE2 overexpression downregulated Ang II type 1 receptor 
expression both in vitro and in vivo. These ﬁndings suggest that 
ACE2 has an important role in the central regulation of blood pres-
sure and volume homeostasis, and some of its eﬀects likely result 
from regulation of Ang II type 1 receptor expression. (Circ Res 
2008; 102: 729–736; doi:10.1161/CIRCRESAHA.107.169110)
Juan Oliver
ACE gene polymorphism and 
losartan treatment in patients with 
type 2 diabetes and nephropathy
The Reduction of Endpoints in NIDDM [non-insulin dependent 
diabetes mellitus] with the Angiotensin II Antagonist Losartan 
(RENAAL) trial evaluated the eﬀects of losartan in patients with 
type 2 diabetes and nephropathy and assessed the association of 
polymorphisms of the ACE gene with outcomes and response 
to therapy.1 Although the study was discontinued, early follow-
up results were subsequently published.   Blood samples were 
collected for each patient on the day of randomization for geno-
typing. Two alleles of the ACE gene (the I and D alleles) were 
detected for each of the 95% of enrolled subjects for whom the 
stored samples were available.
Looking at patients from the RENAAL trial randomized to pla-
cebo alone, Parving et al. describe the relative diﬀerences in natu-
ral history of diabetic nephropathy among persons with diﬀerent 
genotypes. Progression to end-stage renal disease was less frequent 
among patients with the II genotype (21.0%) than among those 
with the ID and DD genotypes (26.5% and 27.1%, respectively; 
Figure). When subjects receiving losartan were compared with 
those receiving placebo, signiﬁcant diﬀerences in the treatment 
aﬀected the progression to end-stage renal disease. Among subjects 
with the II genotype, no detectable reduction in progression was 
found (risk reduction 3.1%, 95% conﬁdence interval (CI) –41.0% 
to 33.3%). Among subjects with either the ID or the DD genotype, 
a statistically signiﬁcant reduction in risk was noted (30.5%, 95% 
CI 13.0% to 44.4%, and 50.1%, 95% CI 27.1% to 65.8%, respec-
tively). The interaction between genotypes and treatment groups 
was statistically signiﬁcant (P = 0.032).
Given the beneﬁt of disruption of the angiotensin axis for car-
diac disease, as well as the limited power of the subgroup analysis, 
this analysis does not support the genotyping of patients to deter-
mine treatment strategy. However, it does provide a foundation for 
future investigations into treatment strategies for kidney disease. A 
treatment strategy with limited overall beneﬁt does not preclude 
a great impact on one particular genotype, nor does it mean that 
the beneﬁt is the same among all subgroups. Such information 
may prove that the treatment of diabetic nephropathy, and perhaps 
other kidney diseases, is within reach. (J Am Soc Nephrol 2008; 19: 
771–779; doi:0.1681/ASN.2007050582)
Lynda Szczech
1N Engl J Med 2001; 345: 861–869
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ACE2 immunofluorescence was dramatically increased in the subfornical 
organ after Ad-hACE2-eGFP (a), but not Ad-eGFP (b), infection. 
 Kaplan-Meier curves of the percentage of patients with the primary 
composite end point in the II (a), ID (b), and DD (c) genotype groups and 
one of its individual components, end-stage renal disease, in the II (d), ID 
(e), and DD (f) genotype groups.
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Association between kidney 
function and incident hypertension
The ability of elevated blood pressure to aﬀect end-stage kidney 
damage and subsequently increase systemic blood pressure is both 
biologically plausible and clinically demonstrated. Now, Kesten-
baum et al. show the risk period over which small decrements 
in kidney function are associated with increased risk of incident 
hypertension in a community-based, observational, cohort study. 
The Multi-Ethnic Study of Atherosclerosis (MESA) included 
adults aged 45–64 years with subclinical cardiovascular disease. 
The analysis included cystatin C levels and urinary albumin-to-
creatinine ratios and correlated them with incident hypertension, 
deﬁned as systolic blood pressure of at least 140 mm Hg, diastolic 
blood pressure of at least 90 mm Hg, or use of an antihypertensive 
medication. Subjects without hypertension, with an estimated 
glomerular filtration rate of at least 60 ml/min, and without 
microalbuminuria at baseline were included. At the relatively 
short follow-up period of a median of 3.1 years, 19.7% of sub-
jects without baseline abnormality in these parameters developed 
hypertension. In the adjusted model, each 15 nmol/l increase in 
cystatin C was associated with a 15% greater incidence of hyperten-
sion (P < 0.17). The relationship between microalbuminuria and 
incident hypertension was not signiﬁcant (the highest sex-speciﬁc 
quartile of albumin-to-creatinine ratio was associated with a 16% 
greater incidence of hypertension, P = 0.192).
Despite their limitations, these data have signiﬁcant poten-
tial beneﬁt to public health. Regardless of whether the relation-
ship between kidney function and incident hypertension goes 
beyond association to one of cause and eﬀect, it is a marker for 
very early kidney disease and could result in greater screening 
for and awareness of declines in renal function. (Ann Intern Med 
2008; 148: 501–508)
Lynda Szczech
Identification of a new renal urate 
transporter, SLC2A9
Unlike other mammals, humans and great apes do not have 
hepatic uricase activity and thus have uniquely high serum 
uric acid concentrations. Uric acid is the end product of purine 
metabolism; approximately 70% of daily urate disposal occurs 
via the kidneys. From 5%–25% of humans have impaired renal 
urate excretion and secondary hyperuricemia. In turn, approxi-
mately 10% of people with hyperuricemia develop gout, arthritis 
that results from deposition of monosodium urate crystals in the 
joint. In a recent study, Vitart et al. conducted a genome-wide 
association scan using 317,503 single-nucleotide polymorphisms 
(SNPs) in 986 individuals in a Croatian isolate population. They 
found serum uric acid to be strongly associated with seven SNPs, 
one located just 5′ to solute carrier family 2, member 9 (SLC2A9), 
and the others within introns of this gene, three of which reached 
genome-wide signiﬁcance after appropriate statistical correction. 
In a follow-up analysis, one of these SNPs explained 5.3% of the 
total unadjusted variance in serum uric acid in women and 
1.7% of the variance in men. These ﬁndings were replicated in 
a population sample from the island of Orkney, United King-
dom. Further, when data from 349 German subjects with low 
fractional excretion of uric acid (≤6.6%) were compared with 
data from 255 normal controls, low urinary excretion of uric 
acid was signiﬁcantly associated with intragenic SLC2A9 SNPs. 
In addition, 484 Scottish individuals with gout compared with 
9,659 controls revealed highly signiﬁcant associations between 
gout and SLC2A9 SNPs.
SLC2A9 has great sequence similarity to the fructose trans-
porter SLC2A5 and has recently been confirmed as both a 
fructose and a glucose transporter. In humans, a long isoform of 
SLC2A9 is mostly expressed in basolateral membranes of proxi-
mal renal tubular cells, the liver, and placenta, whereas a short 
isoform is expressed only in the apical membranes of renal tubu-
lar cells and in placenta. However, in the mouse kidney, SLC2A9 
is expressed in distal convoluted tubules or connecting tubules 
of the renal cortex. Interestingly, SLC2A9 is also expressed in 
chondrocytes from articular cartilage, a key site of uric acid 
deposition in gout. Functional analysis of SLC2A9 through 
expression in Xenopus laevis oocytes showed it to be a urate 
transporter (Figure). SLC2A9 appears to be both a fructose and 
a urate transporter. Fructose is the only sugar known to increase 
serum uric acid, and the increase in its dietary intake over the 
past 30 years has been implicated in rising uric acid levels. (Nat 
Genet 2008; 40: 437– 442; doi:10.1038/ng.106)
Juan Oliver
Transport of [8-14C]uric acid by oocytes expressing SLC2A9 compared with 
negative control oocytes (injected with an unrelated mRNA) and positive 
control oocytes (injected with mRNA of the urate transporter URAT1).
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